(FTXH) First Trust Nasdaq - Ratings and Ratios

The First Trust Nasdaq Pharmaceuticals ETF (FTXH) is designed to track the performance of U.S. companies in the pharmaceutical sector, focusing on liquidity and market ranking. The fund typically allocates at least 90% of its net assets to securities in its underlying index, which is tailored to capture the sectors liquidity and market leadership. As a non-diversified ETF, it may concentrate its holdings in a smaller number of securities, which can amplify both potential returns and risks. For more information, visit the funds website at http://www.ftportfolios.com/.

Ticker Symbol: FTXH | Exchange: NASDAQ | Type: ETF | Country Origin: USA | ETF Category: Health

Based on the provided technical and fundamental data, here is a 3-month forecast:

Short-term momentum is neutral, with the SMA 20 at 27.85 and SMA 50 at 27.53, suggesting a slight upward trend. The SMA 200 at 27.82 indicates a flattish longer-term outlook. ATR of 0.28 signals low volatility, while the average volume of 1876 reflects moderate trading activity. Last price of 28.60 is above the SMA 20 and SMA 50 but slightly below the SMA 200, suggesting potential short-term strength but longer-term stability.

The funds AUM of 15.55M USD is relatively small, which may impact liquidity and increase volatility. However, this size allows for more targeted exposure to the pharmaceutical sector, which could benefit from upcoming catalysts such as FDA approvals or clinical trial results.